Omudhome Ogbru, PharmD
Omudhome Ogbru, PharmD
Dr. Ogbru received his Doctorate in Pharmacy from the University of the Pacific School of Pharmacy in 1995. He completed a Pharmacy Practice Residency at the University of Arizona/University Medical Center in 1996. He was a Professor of Pharmacy Practice and a Regional Clerkship Coordinator for the University of the Pacific School of Pharmacy from 1996-99.
Medical and Pharmacy Editor:
GENERIC NAME: anakinra
BRAND NAME: Kineret
DRUG CLASS AND MECHANISM: Anakinra is a synthetic (man-made), injectable, interleukin-1 receptor antagonist that blocks the effects of human interleukin-1. It is used in the treatment of rheumatoid arthritis. Interleukin-1 (IL-1) is a protein that is produced by many cells in the body. It is found in increased amounts within joints that are inflamed by arthritis. The IL-1 attaches to receptors on the tissues within and surrounding the joints as well as on the cells that are responsible for inflammation, for example, white blood cells. The attachment of IL-1 activates the cells to promote inflammation and release enzymes. The enzymes destroy the cartilage and bone and contribute to pain and swelling of the joints. Anakinra attaches to the IL-1 receptor and prevents IL-1 from attaching to the receptor. Thus, the inflammatory and enzyme-releasing effects of IL-1 are prevented and pain and swelling of the joints are reduced. Anakinra was approved by the Food and Drug Administration in November 2001.
GENERIC AVAILABLE: No
PREPARATIONS: Pre-filled syringes, 100 mg
STORAGE: Anakinra should be refrigerated at 2 C to 8 C (36 F to 46 F)
PRESCRIBED FOR: Anakinra is used for treating the signs and symptoms of moderate to severe rheumatoid arthritis in individuals 18 years of age or older. It is not a first-line drug but is used in individuals who have failed at least one of the disease-modifying drugs that are used to treat rheumatoid arthritis. It can be used alone or in combination with other agents, but it should not be used with drugs that block tumor necrosis factor such as infliximab (Enbrel) and etanercept (Remicade). (See below.)
It is also for used for treatment of neonatal-onset multisystem inflammatory disease (NOMID) due to cryopyrin-associated periodic syndromes (CAPS).
DOSING: The dose of anakinra for rheumatoid arthritis is one subcutaneous injection of 100 mg daily. The dose should be administered at approximately the same time every day.
The dose for treating NOMID is 1-2 mg/kg daily up to a maximum dose of 8 mg/kg.
DRUG INTERACTIONS: Anakinra should not be combined with drugs that block tumor necrosis factor (TNF). Combining anakinra with drugs that block tumor necrosis factor such as infliximab (Enbrel) and etanercept (Remicade) or other drugs that reduce function of the immune system increases the risk of serious infections.
PREGNANCY: Anakinra has not been studied in pregnant women.
NURSING MOTHERS: It is not known if anakinra is excreted in the breast milk of nursing mothers.
SIDE EFFECTS: The most common side effects are reactions at the site of injection, for example, redness, swelling and pain. Other minor side effects include headache, flu-like symptoms, diarrhea and nausea. The most serious side effects are an increase in infections and a decrease in the number of white blood cells (neutropenia) and platelets. Anakinra should not be started in individuals with active infections. Infections occur more frequently when anakinra is used in combination with drugs that block tumor necrosis factor.
Reference: FDA Prescribing Information
Medically Reviewed by a Doctor on 5/27/2014
Report Problems to the Food and Drug Administration
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit the FDA MedWatch website or call 1-800-FDA-1088.
Need help identifying pills and medications?
Back to Medications Index